Michael S. Poirier
President, CEO and Chairman
Michael S. Poirier founded Qualigen in 1996 and is its Chairman, President and Chief Executive Officer. Prior to founding Qualigen, Mr. Poirier was Vice President of Marketing for Ashirus Technologies, Inc., a Minneapolis-based manufacturer of innovative high-precision dispensing pumps and related equipment for the medical industry. From 1993 to 1995, Mr. Poirier was Director of US Area Operations for EnSys, Inc., located in Research Triangle, North Carolina. EnSys developed and manufactured field-portable immunoassay test kits for the environmental remediation industry. From 1991 to 1993, Mr. Poirier was employed by Sanofi Pasteur in Chaska, Minnesota, as a Marketing Manager responsible for launching the ACCESS® Immunoassay System. This novel diagnostic system was later acquired by Beckman-Coulter and is now one of the leading immunoassay test systems worldwide. From 1985 to 1991, Mr. Poirier was employed by Abbott Diagnostics, a division of Abbott Laboratories, Inc. in various marketing and sales positions, including Worldwide Immunoassay Product Manager for the IMx® and AxSym® immunoassay diagnostic systems. Both IMx and later, AxSym, became the leaders in their respective markets. Prior to working at Abbott, Mr. Poirier served as an officer in the United States Navy, assigned to the US Atlantic Fleet. Mr. Poirier holds a B.A. from Providence College and attended the University of Zürich, Switzerland, School of Law.
Since 2016, Ms. Broidrick has served as Senior Vice President, Head of Corporate Development at Viking Therapeutics with responsibility for building and implementing the US and global corporate and business development function. Before that, she was Vice President, Head of Global Marketing Excellence and Business Innovation with EMD Serono (part of Merck KGaA), where she led global and country brand and launch planning, and led strategic transformation initiatives. From 2010-2012, Ms. Broidrick was Vice President, Head of Marketing and Commercialization at Arena Pharmaceuticals, where she led marketing and commercialization planning for a first-in-class obesity drug and also oversaw Portfolio Planning. Before Arena, she held various roles of increasing responsibility at Merck & Co., including Global Brand Leader with P&L accountability; she led Merck & Co.'s new products marketing planning across brands and pipeline for the Asia Pacific region.
Ms. Broidrick holds a BA from Farleigh Dickinson University, completed further undergraduate studies at Wroxton College in England and performed post-graduate work at Farleigh Dickinson.
Richard A. David, M.D. FACS, MMM
Dr. Richard David serves as Chief Medical Officer for Skyline Urology, the largest Urology group in Los Angeles. He also serves as medical director for Skyline’s Advanced Prostate Cancer Center of Excellence. In addition, Dr. David serves as Associate Clinical Professor of Urology for the David Geffen School of Medicine at UCLA. He serves on the Attending Staff in Surgery/Urology at Harbor UCLA Medical Center and Olive View UCLA Medical Center. He is certified by the American Board of Urology. His clinical and research interests include minimally invasive endoscopic treatment for urologic diseases, sexual function and prosthetics, and advanced prostate cancer. He has published extensively and presented at many international conferences in this area. He has received the “Super Doctor” designation 13 times. Dr. David serves as Chief of Surgery at Motion Picture and Television Hospital (MPTVH) in Woodland Hills, CA. In addition to MPTHV, Dr. David serves on staff at Providence St. Joseph Medical Center, Providence Tarzana Medical Center, Valley Presbyterian Hospital, Northridge Hospital Medical Center, Encino Hospital, Sherman Oaks Hospital, Harbor UCLA Medical Center and Olive View UCLA Medical Center. Dr. David obtained his undergraduate education at Stanford University and his medical degree at Thomas Jefferson University in Philadelphia. He also holds a Masters Degree in Medical Management (MMM) from the Marshall School of Business at the University of Southern California. He trained in general surgery and completed his urology residency at UCLA Medical Center in Los Angeles. Dr. David is a fellow of the American College of Surgeons, a member of the American Urological Association, the American Medical Association, and the California Urologic Association. He is also a member in the American Association of Clinical Urologists, American Lithotripsy Society, Society of Laparoendoscopic Surgeons and Society of Urologic Prosthetic Surgeons.
Kurt H. Kruger
Mr. Kruger has enjoyed a 30-year career in Medical Technology. His deep involvement in the field has ranged from product design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an equities research analyst. As a marketing manager at Guidant, now a part of Boston Scientific, he developed the launch plans for the first-ever implantable defibrillator. As a securities analyst he showed perspicuity leading Hambrecht & Quist in providing venture funds for, and then taking public, Ventritex, which was later acquired by St. Jude Medical. After Hambrecht & Quist, Kurt worked as an analyst for Montgomery Securities and Bank of America. Across 20 years of research work, Kurt has overseen the IPOs of over 30 medical products companies, including leadership of the Life Sciences banking effort for WR Hambrecht & Co. Mr. Kruger received a Sc.B. degree in Biomedical Engineering from Brown University; a Master’s degree in Bioengineering from the University of Michigan and a business degree (S.M.) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical post-baccalaureate program at Columbia University.
Mr. Korenberg has served as Executive Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated, a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, since January 2018 and before that as Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated since August 2015. Before joining Ligand, commencing in September 2013, Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Before founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs from July 1999 through August 2013. During his 14 year tenure at Goldman Sachs, Mr. Korenberg was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Before Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read & Co. Inc. where he spent two years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds a B.B.A. in Finance and Accounting from The University of Michigan.
Ira E. Ritter
Mr. Ritter served as Co-Founder, Chief Strategic Officer and Executive Chairman of Ritter’s predecessor from its inception in 2004 through the formation of Ritter Pharmaceuticals, Inc. in 2008 and he has served in those positions with Ritter since 2008. Mr. Ritter has extensive experience creating and building diverse business enterprises and has provided corporate management, strategic planning and financial consulting for a wide range of market segments including; health product related national distribution and private label production, television and publishing. He assisted taking Ritter public on Nasdaq and Martin Lawrence Art Galleries public on the The New York Stock Exchange. Since 2010, Mr Ritter has also acted as a managing partner of Stonehenge Partners. Mr. Ritter has a long history of public service that includes appointments by three Governors to several State of California Commissions including eight years as Commissioner on the California Prison Industry Authority. He has guest lectured at University of Southern California Marshall School of Business and Pepperdine University Graziadio School of Business, where he also serves as an advisory board member to Pepperdine’s Graduate School of Education and Psychology, Social Entrepreneurship and Change Program. He has served on the boards of directors for Vitavis Laboratories and SCWorx.